Calcineurin inhibitors may augment the effects of antifungal drugs in microbiological assays. We examined this interaction in a microbiological assay for posaconazole. No effect was observed. However, concurrent or recently discontinued treatment with other antifungal drugs caused false-positive results, emphasizing a limitation of microbiological assays for antifungal drug level measurement.
Posaconazole is a broad-spectrum antifungal agent used for the prevention and treatment of serious fungal infections. Blood levels are highly variable, and low blood levels are associated with treatment failure in aspergillosis (5, 7) . These studies suggest that levels of at least 1 g/ml are desirable for the treatment of aspergillosis and that drug levels should be monitored. Posaconazole levels can be measured by high-pressure liquid chromatography (4), liquid chromatography/mass spectroscopy (1) , and microbiological assay (3) . High-pressure liquid chromatography and liquid chromatography/mass spectroscopy assays are difficult to develop, require expensive equipment and skilled personnel, and are not widely available. Microbiological assays overcome these limitations but may be affected by coadministration of other drugs with antifungal activity. Calcineurin inhibitors are used to prevent rejection or graft-versus-host disease in transplant patients and often are coadministered with antifungal drugs. They also exhibit antifungal properties (6) , which may interfere with monitoring of antifungal blood levels by microbiological assay. To explore these factors, we examined the effects of calcineurin inhibitors on posaconazole levels via microbiological assay.
Posaconazole (lot no. IRQ-PAZ-04-X-25M1-B; ScheringPlough Research Institute, Kenilworth, NJ) was dissolved in dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO) to a concentration of 1.0 mg/ml. Posaconazole standards (20.0, 5.0, 2.5, 1.25, 0.62, and 0.15 g/ml) and controls (10.0 and 0.31 g/ml) were made by serially diluting the 1.0-mg/ml dimethyl sulfoxide stock solution in normal human serum (Scantibodies, Santee, CA). A 10ϫ yeast nitrogen base (YNB) broth was made by dissolving 6.7 g of YNB powder (Becton Dickinson and Company, Sparks, MD) and 5.0 g of dextrose (Fisher; D16-500) in a final volume of 100 ml of sterile water. A 2ϫ YNB broth was made by dissolving 6.7 g of YNB powder, 10.0 g of dextrose, and 5.9 g of sodium citrate tribasic dihydrate (Sigma, St. Louis, MO) in a final volume of 500 ml of sterile water and was adjusted to pH 7.0. Difco Noble Agar (2ϫ) was made by dissolving 2.55 g of Difco Noble Agar (Fisher Scientific, Chicago, IL) in a final volume of 85 ml of sterile water.
For preparation of the plates used in the assay, Candida kefyr (ATCC 46764) was suspended in 1ϫ YNB, made by diluting 0.5 ml of 10ϫ YNB with 4.5 ml of sterile water. The suspension was adjusted to 85 to 91% transmittance at a wavelength of 590 nm and then incubated at 37°C until the transmittance was between 65% and 70%, a process that usually required about 5 h. The C. kefyr broth (1.5 ml) was mixed into 85 ml of 2ϫ YNB. This solution was then mixed into the 85 ml of 2ϫ Difco Noble Agar and then poured into Corning 245-by 245-by 20-mm plates. After the plates were allowed to solidify for 20 min, 5-mm-diameter wells were bored with a sterile cork borer, and the agar was aspirated out of the plates. The wells were loaded with 50 l of the desired sample and placed into a 37°C incubator for 14 to 18 h. The plates were read with Mitutoyo Corporation Digimatic calipers. Two measurements were taken for each sample and entered into a plot. A linear regression line of the form y ϭ b 0 ϩ b 1 (x), where y is the log 10 of the measured diameter, was used to fit the measured standards. For the assay to be considered acceptable, the R 2 value of the regression line must be Ͼ0.95, the 10.0-g/ml control must fall between 8 and 12 g/ml, and the 0.31-g/ml control must fall between 0.186 and 0.372 g/ml. Fluconazole concentrations were determined by gas-liquid chromatography (GLC) at the Fungus Testing Laboratory (San Antonio, TX) (2).
Residual deidentified plasma specimens from 30 transplant patients receiving cyclosporine, tacrolimus, sirolimus, or a combination of tacrolimus and sirolimus were obtained from the clinical laboratory at Clarian Hospital, Indianapolis, IN, in a project approved as an exempt study by the Institutional Review Board. All patients were taking multiple medications, usually mycophenolate and corticosteroids and occasionally antifungal agents. Patients known to be receiving a concurrent antifungal agent were excluded from the analysis. The samples were stored at Ϫ80°C upon receipt at MiraVista Diagnostics (Indianapolis, IN). Ten serum specimens were obtained from healthy laboratory personnel.
Five patients were excluded because, after review of the results, they were found in retrospect to have been receiving voriconazole (n ϭ 3) or fluconazole (n ϭ 2). The posaconazole microbiological assay was positive for all five patients at levels ranging from 1.09 g/ml to Ͼ20 g/ml. For the remaining 25 patients, key findings are shown in Table 1 . False-positive results for posaconazole were observed in nine patients, ranging from Ͻ0.15 to 0.79 g/ml. Upon repeat testing, six were reproducibly positive at concentrations ranging from Ͻ0.15 to 0.76 g/ml. Five of these six patients had received fluconazole within 3 to 11 days of the specimen being tested for posaconazole. The six false-positive specimens were tested for fluconazole by GLC, and four gave positive results ranging from 2.05 to 4.26 g/ml. Because of the false-positive results for the two patients whose blood specimens were negative for fluconazole, 10 specimens from healthy subjects were tested, and none were positive for posaconazole.
To directly test inhibitory activity, normal human serum was spiked with posaconazole and the calcineurin inhibitors to the concentrations specified in Table 2 . The mixture contained equivalent volumes of posaconazole and the calcineurin inhibitor (25 l of each per well). The calcineurin inhibitors did not produce a zone of inhibition and did not affect the zone size when added to posaconazole (Table 2) .
Microbiological assays for antifungal agents are not specific, as inhibition of the growth of the indicator organism may be influenced by any drug that the patient is taking. This limitation is clearly illustrated in the patients who were taking voriconazole or fluconazole at the time of testing. Interestingly, false-positive results were also observed for patients who had recently discontinued fluconazole but in whom fluconazole was still detectable by GLC. Interference caused by concurrent or recently administered antifungal agents, but not calcineurin inhibitors, is a significant limitation of the microbiological method for antifungal drug level measurement. d Skipped numbers (6, 9, 16, 17, and 23) represent specimens from patients who were excluded because they were taking fluconazole or voriconazole.
e The posaconazole concentration was Ͻ0.15 g/ml when initially tested but undetectable when repeated. 
